Nxera Pharma has participated in a Series A financing for NewCo, a company it co-founded, to accelerate preclinical studies of a GPCR-targeted program. Nxera is eligible for up to $275 million in milestone payments.
May 11, 2026
Amount Raised
$275 Million
Round Type
Series A
TokyoBiotechnologyPharmaceutical
Description
Nxera Pharma announced its involvement in a Series A financing for NewCo, aimed at advancing a GPCR-targeted program. The financing will support preclinical studies and preparation for global clinical trials. Nxera retains rights in Japan and parts of Asia-Pacific while securing milestone payments. This partnership seeks to enhance the program's value for shareholders and patients alike.
Who to call at Nxera Pharma Ltd, and when
A new round usually means Nxera Pharma Ltd is about to hire and buy. The teams that reach out first get the meeting.
An alert the day Nxera Pharma Ltd raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at Nxera Pharma Ltd, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Nxera Pharma Ltd. With Fundz connected, it knows.
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
Nxera Pharma Ltd
Location
Tokyo, Tokyo, Japan
About
Nxera Pharma (formerly Sosei Heptares) is a technology powered biopharma company, in pursuit of new specialty medicines to improve the lives of patients with unmet needs in Japan and globally.
In addition to several products being commercialized in Japan, we are advancing an extensive pipeline of over 30 active programs from discovery through to late clinical stage internally and in partnership with leading pharma and biotech companies. This pipeline is focused on addressing major unmet needs in some of the fastest-growing areas of medicine across neurology, GI and immunology, metabolic disorders and rare diseases, and leverages the power of our unique and industry leading GPCR-targeted structure-based drug discovery “NxWave” platform to provide a sustainable source of best- or first-in-class candidates.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Nxera Pharma Ltd raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
TokyoBiotechnologyPharmaceutical